Feb 13, 2025 8:00am EST RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery
Feb 11, 2025 7:00am EST RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock